Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

CRISPR and crRNAs

CRISPR and crRNAs

Bacteria and archaea are susceptible to viral infections just like eukaryotes; therefore, they have developed a unique adaptive immune system to protect themselves. Clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins (CRISPR-Cas) are present in more than 45% of known bacteria and 90% of known archaea.
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Experimental Models of Autoimmune Hepatitis: Disease Fidelity and Translational Relevance.

Liver international : official journal of the International Association for the Study of the Liver·2026

Same author

Graft-Specific Regulatory T Cells for Long-Lasting, Local Tolerance Induction.

Cells·2024

Same author

Development of Beta-Amyloid-Specific CAR-Tregs for the Treatment of Alzheimer's Disease.

Cells·2023

Same author

Generation of Chimeric Antigen Receptors against Tetraspanin 7.

Cells·2023

Same author

The Detrimental Role of Regulatory T Cells in Nonalcoholic Steatohepatitis.

Hepatology communications·2021

Same author

Anti-CD20 Therapy Alters the Protein Signature in Experimental Murine AIH, but Not Exclusively towards Regeneration.

Cells·2021

Search research articles

Related Experiment Video

Updated: Jul 17, 2026

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Engineering CAR-Tregs with Phage-Selected scFv Enables a New Paradigm for Immune Regulation.

Fatih Noyan¹, Matthias Hardtke-Wolenski^1,2

¹Dept. of Gastroenterology, Hepatology, Infectious Disease and Endocrinology, Hannover Medical School, Hannover, Germany.

Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology

|July 16, 2026

Summary

This study introduces a new phage-display method to discover better binders for engineered regulatory T cells (Tregs). This approach aims to improve Treg stability and function for immune tolerance therapies.

Keywords:

FOXP3 Treg cell cell biology chimeric antigen receptor immune system immune tolerance monoclonal antibody scfv antibodies

More Related Videos

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Precise Phage Mutagenesis with NgTET-Assisted CRISPR-Cas Systems

Precise Phage Mutagenesis with NgTET-Assisted CRISPR-Cas Systems

Published on: October 14, 2025

Related Experiment Videos

Last Updated: Jul 17, 2026

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Precise Phage Mutagenesis with NgTET-Assisted CRISPR-Cas Systems

Precise Phage Mutagenesis with NgTET-Assisted CRISPR-Cas Systems

Published on: October 14, 2025

Area of Science:

Immunology
Biotechnology
Cell Therapy

Background:

Regulatory T cells (Tregs) are crucial for immune tolerance.
Current CAR-Treg therapies face challenges with antigen-specific cell therapy development.
Existing CAR-Treg designs using effector-optimized scFvs may cause instability.

Purpose of the Study:

To propose a novel phage-first binder discovery framework for CAR-Tregs.
To link phage-display selection pressures to scFv properties and Treg cell fate.
To define an optimal tonic signaling window for durable immune regulation.

Main Methods:

Utilizing a phage-display selection and counter-selection strategy.
Hypothesizing that multi-parameter selection enriches for specific scFv biophysical properties.
Outlining a two-phase roadmap for validation: bench triage and mechanistic/preclinical studies.

Main Results:

The proposed framework aims to enrich scFvs with moderate affinity and low polyspecificity.
Hypothesized that selected scFvs will reduce tonic signaling and enhance Treg stability.
The study sets the stage for determining how scFv characteristics influence Treg function.

Conclusions:

A phage-first approach can yield improved binders for CAR-Treg development.
Optimizing scFv properties is key to enhancing Treg stability and function.
This framework provides a pathway to durable immune regulation through engineered Tregs.